Kyung Chu on Treating Different Subtypes of the KRAS Mutation

Video

Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.

Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.

Typically, EGFR inhibitors are used in lung and colon cancer to treat patients with KRAS mutations. However, this therapy has mixed clinical outcomes for the patients, varying by their mutation subtype. Chu emphasizes that nurses and doctors must use the EGFR inhibitors wisely, and consider the patient’s subtype when deciding on a treatment plan.

Related Videos
Related Content
Image of "FDA Approved" in blue and green.

FDA Approves First Radioactive Drug for Children With SSTR-Positive GEP-NETs

April 23rd 2024
Article

Lutetium Lu 177 dotatate was approved by the FDA for children aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

The Vitals

Nicole Gay Shares How She Counsels Patients on Lung Cancer Screenings

November 15th 2023
Podcast

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

FDA Approves First ALK Inhibitor for Adjuvant Therapy in Early-Stage NSCLC

April 18th 2024
Article

Alectinib was approved for the treatment of patients with ALK-positive non-small cell lung cancer after surgical resection.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Opinion: Osimertinib Plus Chemo May Enhance Outcomes in Metastatic EGFR-Mutated Lung Cancer

Opinion: Osimertinib Plus Chemo May Enhance Outcomes in Metastatic EGFR-Mutated Lung Cancer

April 15th 2024
Article

Oncology nurses play a vital role in informing patients about the importance of molecular testing and brain imaging in EGFR-mutated lung cancer.

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit

April 12th 2024
Article

Over the last 5 years, 57% of drugs approved by the FDA for a cancer-related indication did not show a clinical benefit in confirmatory studies.

© 2024 MJH Life Sciences

All rights reserved.